FDA Approves Sirolimus Protein-Bound for Perivascular Epithelioid Cell Tumors

The FDA has approved sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro™, Aadi Bioscience) for patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor. "Malignant perivascular epithelioid cell tumor is a rare, aggressive sarcoma," wrote Andrew J. Wagner, MD, PhD, Medical Director of Ambulatory Oncology at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, and colleagues, in t...
Continue reading

Oncology Data Advisor Announces Formation of Editorial Board

ROCHELLE PARK, NJ––September 28, 2021 – Oncology Data AdvisorTM, a multimedia site that publishes expert perspectives, news, and original research to foster improved understanding of emerging data in oncology, has announced the addition of an editorial board that will help plan and create relevant content for the multidisciplinary cancer care team.

Continue reading

World Cancer Research Day With Dr. Thomas Abrams

Thomas Abrams, MD.

On World Cancer Research Day, Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School and the new Editor in Chief of Oncology Data Advisor, discusses his career as a gastrointestinal cancer researcher, the recent advancements that have been made, and the progress that is on the horizon in this field. 

Continue reading

Identifying Novel Therapies for Multiple Myeloma: Paul Richardson, MD

In the following interview, Dr. Paul Richardson, the Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, discusses some important factors in the development of drugs to target "the queen of immunological cancers," multiple myeloma, and why this disease is difficult to cure. Recently, he led the development and clinical trials of the novel targeted cytotoxic peptide-drug, melphalan flufenamide (Pepaxto®, Oncop...
Continue reading

Lisocabtagene Maraleucel Approved for Relapsed/Refractory Large B-Cell Lymphomas

The FDA has approved lisocabtagene maraleucel (Breyanzi®, Juno Therapeutics) for patients with relapsed/refractory large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DCBLC transformed from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, and grade 3B follicular lymphoma, who have progressive disease following at least two prior lines of systemic therapy. Lisocabtagene maraleucel is not indicated for patie...
Continue reading

Vitamin D Supplements for Reducing Advanced Cancer Risk: Paulette Chandler, MD, MPH

In a study recently published in JAMA Network Open, a team of investigators led by Paulette Chandler, MD, MPH, found that vitamin D supplementation is associated with a decreased risk of developing advanced cancer, particularly among individuals with a normal body mass index (BMI). In this interview with i3 Health, Dr. Chandler, an Assistant Professor of Medicine at Harvard Medical School, discusses the significance of these results and the ongoing research investigating vitamin D supplementatio...
Continue reading

Vitamin D Supplements May Reduce the Risk of Developing Advanced Cancer

In individuals without cancer, vitamin D supplementation may decrease the risk of developing advanced cancer, especially for those with a normal body mass index (BMI), according to a recent analysis of a phase 3 trial. "Vitamin D may decrease tumor invasiveness and propensity to metastasize, leading to reduced cancer mortality," write the investigators, led by first author Paulette D. Chandler, MD, MPH, Assistant Professor of Medicine at Harvard Medical School. "Vitamin D may have a role in redu...
Continue reading

Nivolumab/Ipilimumab for Advanced Renal Cell Carcinoma: Meredith Regan, ScD

Patients with advanced renal cell carcinoma (RCC) who receive combination PD-1/CTLA-4 blockade can experience periods of durable benefit and toxicity after treatment discontinuation. According to results of the phase 3 CheckMate 214 trial presented by Meredith Regan, ScD, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, nivolumab/ipilimumab prolongs treatment-free survival, both with and without toxicity, in patients with previously untreated advanced clear cell RCC. In...
Continue reading

Advanced Renal Cell Carcinoma: Nivolumab/Ipilimumab Improves Treatment-Free Survival

Nivolumab/ipilimumab prolongs treatment-free survival with and without toxicity in patients with untreated advanced renal cell carcinoma (RCC), according to an updated analysis of the phase 3 CheckMate 214 trial presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. "Conventional measures may not fully characterize the impact of immuno-oncology agents," comment the investigators in their presentation abstract, led by first author Meredith Regan, ScD, Associate Profe...
Continue reading

Neoadjuvant Nivolumab/Ipilimumab for Oral Cavity SCC: Jonathan Schoenfeld, MD, MPH

Due to intensive treatments, severe side effects, and a high rate of recurrence, oral cavity squamous cell carcinoma (SCC) is a challenging disease associated with poor outcomes. According to a recent study, neoadjuvant nivolumab alone or in combination with ipilimumab may be a safe and effective treatment for patients with oral cavity SCC undergoing surgical resection. In this interview, Jonathan Schoenfeld, MD, MPH, Associate Professor of Radiation Oncology at Harvard Medical School and first ...
Continue reading

Has Life Expectancy for Adult Survivors of Childhood Cancer Improved?

Scientists recently discovered that improved cancer treatment approaches over time correlate with higher life expectancy in adult survivors of childhood cancer. As cancer treatment evolves to be more effective, more patients are surviving, with some even living long lives disease free. In order to determine if life expectancy also rises with evolving treatment, the investigators examined data derived from the Childhood Cancer Survivor Study, which included data on 5-year survivors of childhood c...
Continue reading

Predicting Relapse in Pancreatic Neuroendocrine Tumors

Researchers have found a new way to classify non-functional pancreatic neuroendocrine tumors (PNETs) in order to predict which patients will experience relapse. Most PNETs are non-functional, meaning that they do not release excess hormones into the bloodstream. In current practice, patients whose non-functional PNETs are larger than 2 cm are considered at the highest risk of metastatic recurrence following surgery. "As clinical behaviors [of non-functional PNETs] vary widely and distant metasta...
Continue reading

Acute Myeloid Leukemia: Potential Therapeutic Targets

Even though targeted therapies are often efficacious in acute myeloid leukemia (AML), treatment resistance is sometimes inevitable. Mutations in isocitrate dehydrogenase (IDH) enzymes occur in approximately 20% of AML cases and could be a potential factor in treatment resistance. In order to produce a more effective therapy, researchers tracked the evolution of leukemia from mutant IDH2 dependence to independence and found two vulnerabilities of IDH2-mutant leukemia that can serve as potential t...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.